Iron chelators can protect against oxidative stress through ferryl heme reduction

Free Radical Biology and Medicine

Volumn 44, Issue 3, 2008, Pages 264-273

  Reeder, Brandon J ^a   Hider, Robert C ^b   Wilson, Michael T ^a  

^a UNIVERSITY OF ESSEX   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Ferryl; Free radicals; Heme to protein cross linking; Iron chelators; Myoglobin; Oxidative damage

Indexed keywords

1 ETHYL 3 HYDROXYPYRID 2 ONE; 1 HYDROXYPYRIDINE 2 ONE; 1,6 DIMETHYL 2 (N 4', N PROPYLSUCCINAMIDO)METHYL 3 HYRDOXYPYRIDIN 4 ONE; 8 QUINOLINOL; CP 02; CP 358; DEFERIPRONE; DEFEROXAMINE; FERRYL HEME; FERRYLMYOGLOBIN; HEME; HYDROXYUREA; IRON CHELATING AGENT; MALTOL; PARA CRESOL; PHENOL; THIOANISOLE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; DRUG MECHANISM; MOLECULAR STABILITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN INTERACTION; REDUCTION;

ANIMALS; HEME; IRON; IRON CHELATING AGENTS; METMYOGLOBIN; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 38149109843     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2007.08.006     Document Type: Article

References (47)

1. Turner J.J., Rice-Evans C.A., Davies M.J., and Newman E.S. Free radicals, myocytes and reperfusion injury. Biochem. Soc. Trans. 18 (1990) 1056-1059
2. Miller Y.I., Felikman Y., and Shaklai N. Hemoglobin induced apolipoprotein B crosslinking in low-density lipoprotein peroxidation. Arch. Biochem. Biophys. 326 (1996) 252-260
3. Steward A., Williamson I., Madigan T., Bretnall A., and Hassan I.F. An improved animal model for studying desferrioxamine. Br. J. Haematol. 95 (1996) 654-659
4. Reeder B.J., and Wilson M.T. Desferrioxamine inhibits production of cytotoxic heme to protein cross-linked myoglobin: a mechanism to protect against oxidative stress without iron chelation. Chem. Res. Toxicol. 18 (2005) 1004-1011
5. Morehouse K.M., Flitter W.D., and Mason R.P. The enzymatic oxidation of Desferal to a nitroxide free radical. FEBS Lett. 222 (1987) 246-250 (Published erratum appears in FEBS Lett 233:440; 1988)
6. Halliwell B. Use of desferrioxamine as a 'probe' for iron-dependent formation of hydroxyl radicals: evidence for a direct reaction between desferal and the superoxide radical. Biochem. Pharmacol. 34 (1985) 229-233
7. Kayyali R., Pannala A.S., Khodr H., and Hider R.C. Comparative radical scavenging ability of bidentate iron (III) chelators. Biochem. Pharmacol. 55 (1998) 1327-1332
8. Moore K.P., Holt S.G., Patel R.P., Svistunenko D.A., Zackert W., Goodier D., Reeder B.J., Clozel M., Anand R., Cooper C.E., Morrow J.D., Wilson M.T., Darley-Usmar V., and Roberts II L.J. A causative role for redox cycling of myoglobin and its inhibition by alkalinization in the pathogenesis and treatment of rhabdomyolysis-induced renal failure. J. Biol. Chem. 273 (1998) 31731-31737
9. Sakamoto M., Takaki E., Yamashita K., Watanabe K., Tabuchi S., Watanabe T., and Satoh K. Nonenzymatic derived lipid peroxide, 8-iso-PGF2 alpha, participates in the pathogenesis of delayed cerebral vasospasm in a canine SAH model. Neurol. Res. 24 (2002) 301-306
10. Vollmer D.G., Hongo K., Ogawa H., Tsukahara T., and Kassell N.F. A study of the effectiveness of the iron-chelating agent deferoxamine as vasospasm prophylaxis in a rabbit model of subarachnoid hemorrhage. Neurosurgery 28 (1991) 27-32
11. Arthur A.S., Fergus A.H., Lanzino G., Mathys J., Kassell N.F., and Lee K.S. Systemic administration of the iron chelator deferriprone attenuates subarachnoid hemorrhage-induced cerebral vasospasm in the rabbit. Neurosurgery 41 (1997) 1385-1391 (discussion 1391-1382)
12. Torri C., Cafe C., Adinolfi D., Gaetani P., Rodriguez y Baena R., and Marzatico F. Synaptosomal iron-dependent lipid peroxidation inhibition after subarachnoid hemorrhage by lazaroid in vivo treatment. Mol. Chem. Neuropathol. 30 (1997) 15-24
13. Reeder B.J., Sharpe M.A., Kay A.D., Kerr M., Moore K., and Wilson M.T. Toxicity of myoglobin and haemoglobin: oxidative stress in patients with rhabdomyolysis and subarachnoid haemorrhage. Biochem. Soc. Trans. 30 (2002) 745-748
14. Nath K.A., Haggard J.J., Croatt A.J., Grande J.P., Poss K.D., and Alam J. The indispensability of heme oxygenase-1 in protecting against acute heme protein-induced toxicity in vivo. Am. J. Pathol. 156 (2000) 1527-1535
15. Ono S., Komuro T., and Macdonald R.L. Heme oxygenase-1 gene therapy for prevention of vasospasm in rats. J. Neurosurg. 96 (2002) 1094-1102
16. Christodoulides N., Durante W., Kroll M.H., and Schafer A.I. Vascular smooth muscle cell heme oxygenases generate guanylyl cyclase-stimulatory carbon monoxide. Circulation 91 (1995) 2306-2309
17. Morita T., and Kourembanas S. Endothelial cell expression of vasoconstrictors and growth factors is regulated by smooth muscle cell-derived carbon monoxide. J. Clin. Invest. 96 (1995) 2676-2682
18. Otterbein L.E., Mantell L.L., and Choi A.M. Carbon monoxide provides protection against hyperoxic lung injury. Am. J. Physiol. 276 (1999) L688-L694
19. Roberts L.J., and Morrow J.D. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic. Biol. Med. 28 (2000) 505-513
20. Morrow J.D., Awad J.A., Boss H.J., Blair I.A., and Roberts II L.J. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc. Natl. Acad. Sci. USA 89 (1992) 10721-10725
21. Holt S., Reeder B., Wilson M., Harvey S., Morrow J.D., Roberts II L.J., and Moore K. Increased lipid peroxidation in patients with rhabdomyolysis. Lancet 353 (1999) 1241
22. Morrow J.D., Hill K.E., Burk R.F., Nammour T.M., Badr K.F., and Roberts II L.J. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. USA 87 (1990) 9383-9387
23. Salahudeen A.K., Oliver B., Bower J.D., and Roberts II L.J. Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int. 60 (2001) 1525-1531
24. Catalano C.E., Choe Y.S., and Ortiz de Montellano P.R. Reactions of the protein radical in peroxide-treated myoglobin: formation of a heme-protein cross-link. J. Biol. Chem. 264 (1989) 10534-10541
25. Reeder B.J., Svistunenko D.A., Sharpe M.A., and Wilson M.T. Characteristics and mechanism of formation of peroxide-induced heme to protein cross-linking in myoglobin. Biochemistry 41 (2002) 367-375
26. Osawa Y., Nakatsuka K., Williams M.S., Kindt J.T., and Nakatsuka M. Reactions of reactive metabolites with hemoproteins-toxicological implications: covalent alteration of hemoproteins. Adv. Exp. Med. Biol. 387 (1996) 37-45
27. 2: toxicological implications. Free Radic. Biol. Med. 21 (1996) 35-41
28. Vuletich J.L., Osawa Y., and Aviram M. Enhanced lipid oxidation by oxidatively modified myoglobin: role of protein-bound heme. Biochem. Biophys. Res. Commun. 269 (2000) 647-651
29. Dobbin P.S., Hider R.C., Hall A.D., Taylor P.D., Sarpong P., Porter J.B., Xiao G., and van der Helm D. Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential. J. Med. Chem. 36 (1993) 2448-2458
30. Streater M., Taylor P.D., Hider R.C., and Porter J. Novel 3-hydroxy-2(1H)-pyridinones: synthesis, iron(III)-chelating properties, and biological activity. J. Med. Chem. 33 (1990) 1749-1755
31. Kayyali R., Porter J.B., Liu Z.D., Davies N.A., Nugent J.H., Cooper C.E., and Hider R.C. Structure-function investigation of the interaction of 1- and 2-substituted 3-hydroxypyridin-4-ones with 5-lipoxygenase and ribonucleotide reductase. J. Biol. Chem. 276 (2001) 48814-48822
32. Reeder B.J., and Wilson M.T. Mechanism of reaction of myoglobin with the lipid hydroperoxide hydroperoxyoctadecadienoic acid. Biochem. J. 330 (1998) 1317-1323
33. Walters F.P., Kennedy F.G., and Jones D.P. Oxidation of myoglobin in isolated adult rat cardiac myocytes by 15-hydroperoxy-5,8,11,13-eicosatetraenoic acid. FEBS Lett. 163 (1983) 292-296
34. Berzofsky J.A., Peisach J., and Blumberg W.E. Sulfheme proteins. I. Optical and magnetic properties of sulfmyoglobin and its derivatives. J. Biol. Chem. 246 (1971) 3367-3377
35. Osawa Y., and Korzekwa K. Oxidative modification by low levels of HOOH can transform myoglobin to an oxidase. Proc. Natl. Acad. Sci. USA 88 (1991) 7081-7085
36. Fox Jr. J.B., Nicholas R.A., Ackerman S.A., and Swift C.E. A multiple wavelength analysis of the reaction between hydrogen peroxide and metmyoglobin. Biochemistry 13 (1974) 5178-5186
37. Lardinois O.M., and Ortiz de Montellano P.R. Autoreduction of ferryl myoglobin: discrimination among the three tyrosine and two tryptophan residues as electron donors. Biochemistry 43 (2004) 4601-4610
38. Reeder, B. J.; Cutruzzola, F.; Bigotti, M.; Hider, R. C.; Wilson, M. T. Tyrosine as a redox active center in electron transfer to ferryl heme in globins. Free Radic. Biol. Med. (in press); 2007.
39. Froman C., and Smith A.C. Metabolic acidosis of the cerebrospinal fluid associated with subarachnoid haemorrhage. Lancet 1 (1967) 965-967
40. Campion D.S., Arias J.M., and Carter N.W. Rhabdomyolysis and myoglobinuria: association with hypokalemia of renal tubular acidosis. JAMA 220 (1972) 967-969
41. McCarron D.A., Elliott W.C., Rose J.S., and Bennett W.M. Severe mixed metabolic acidosis secondary to rhabdomyolysis. Am. J. Med. 67 (1979) 905-908
42. Reeder B.J., and Wilson M.T. Hemoglobin and myoglobin associated oxidative stress: from molecular mechanisms to disease states. Curr. Med. Chem. 12 (2005) 2741-2751
43. Reeder B.J., Svistunenko D.A., Cooper C.E., and Wilson M.T. The radical and redox chemistry of myoglobin and hemoglobin: from in vitro studies to human pathology. Antioxid. Redox Signaling 6 (2004) 954-966
44. Rice-Evans C., Okunade G., and Khan R. The suppression of iron release from activated myoglobin by physiological electron donors and by desferrioxamine. Free Radic. Res. Commun. 7 (1989) 45-54
45. Silaghi-Dumitrescu R., Reeder B.J., Nicholls P., Cooper C.E., and Wilson M.T. Ferryl haem protonation gates peroxidatic reactivity in globins. Biochem. J. 403 (2007) 391-395
46. Huang J., Zou Z., Kim-Shapiro D.B., Ballas S.K., and King S.B. Hydroxyurea analogues as kinetic and mechanistic probes of the nitric oxide producing reactions of hydroxyurea and oxyhemoglobin. J. Med. Chem. 46 (2003) 3748-3753
47. Rice-Evans C., Baysal E., Singh S., Jones S.A., and Jones J.G. The interactions of desferrioxamine and hydroxypyridone compounds with haemoglobin and erythrocytes. FEBS Lett. 256 (1989) 17-20